Application of hybrid approach based on empirical and physiological concept for predicting pharmacokinetics in humans-usefulness of exponent on prospective evaluation of predictability

Drug Metabolism and Disposition

Volumn 41, Issue 2, 2013, Pages 498-507

  Sayama, Hiroyuki ^a   Komura, Hiroshi ^a   Kogayu, Motohiro ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; DIAZEPAM; DILTIAZEM; EPIROPRIM; FELODIPINE; MIDAZOLAM; NICARDIPINE; NITRENDIPINE; OXAZEPAM; PHENAZONE; PROPAFENONE; PROPRANOLOL; THEOPHYLLINE; TOLCAPONE; VERAPAMIL;

ACCURACY; ALLOMETRY; ANALYTICAL ERROR; ARTICLE; DRUG CLEARANCE; DRUG DISTRIBUTION; IN VITRO STUDY; INTERMETHOD COMPARISON; MATHEMATICAL ANALYSIS; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; SPECIES DIFFERENCE; STEADY STATE;

ANIMALS; BODY WEIGHT; DOGS; HAPLORHINI; HUMANS; LIVER; METABOLIC CLEARANCE RATE; MICE; MICROSOMES, LIVER; MODELS, BIOLOGICAL; ORGAN SIZE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PROSPECTIVE STUDIES; RABBITS; RATS; REPRODUCIBILITY OF RESULTS; SPECIES SPECIFICITY;

EID: 84872689874     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048819     Document Type: Article

References (40)

1. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, and Pelkonen OR, et al. (2007) Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 8:33-45. (Pubitemid 46043890)
2. Boxenbaum H and Ronfeld R (1983) Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 245:R768-R775. (Pubitemid 14219457)
3. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, and Gilissen RA (2007) Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 35:1766-1780. (Pubitemid 47481568)
4. Dedrick R, Bischoff KB, and Zaharko DS (1970) Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 54:95-101.
5. Fura A, Vyas V, Humphreys W, Chimalokonda A, and Rodrigues D (2008) Prediction of human oral pharmacokinetics using nonclinical data: examples involving four proprietary compounds. Biopharm Drug Dispos 29:455-468.
6. Goteti K, Garner CE, and Mahmood I (2010) Prediction of human drug clearance from two species: a comparison of several allometric methods. J Pharm Sci 99:1601-1613.
7. Hallifax D, Foster JA, and Houston JB (2010) Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm Res 27:2150-2161.
8. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, and Webster R, et al. (2009) Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49: 513-533.
9. Huh Y, Smith DE, and Feng MR (2011) Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs. Xenobiotica 41:972-987.
10. Ito K and Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103-112. (Pubitemid 40558152)
11. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, and Rostami-Hodjegan A (2009) The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 5:211-223.
12. Jones HM, Parrott N, Jorga K, and Lavé T (2006) A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45:511-542.
13. Jones HM, Gardner IB, Collard WT, Stanley PJ, Oxley P, Hosea NA, Plowchalk D, Gernhardt S, Lin J, and Dickins M, et al. (2011) Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling. Clin Pharmacokinet 50:331-347.
14. Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, and Galetin A, et al. (2012) Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos 40:1007-1017.
15. Lave T, Levet-Trafit B, Schmitt-Hoffmann AH, Morgenroth B, Richter W, and Chou RC (1995) Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations. J Pharm Sci 84:1285-1290.
16. Lave T, Coassolo P, Ubeaud G, Brandt R, Schmitt C, Dupin S, Jaeck D, and Chou RC (1996a) Interspecies scaling of bosentan, a new endothelin receptor antagonist and integration of in vitro data into allometric scaling. Pharm Res 13:97-101. (Pubitemid 26076303)
17. Lave T, Dupin S, Schmitt M, Kapps M, Meyer J, Morgenroth B, Chou RC, Jaeck D, and Coassolo P (1996b) Interspecies scaling of tolcapone, a new inhibitor of catechol- O-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. Xenobiotica 26:839-851. (Pubitemid 26298162)
18. Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, and Coassolo P (1997) Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J Pharm Sci 86:584-590. (Pubitemid 27203406)
19. Mahmood I and Balian JD (1996) Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887-895. (Pubitemid 26343083)
20. Mahmood I (2002) Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling. A comparative study of the two approaches. Drug Metabol Drug Interact 19:49-64.
21. Mahmood I (2006) Prediction of human drug clearance from animal data: application of the rule of exponents and 'fu Corrected Intercept Method' (FCIM). J Pharm Sci 95: 1810-1821. (Pubitemid 44229587)
22. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, and Sugiyama Y (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316-1324. (Pubitemid 32896581)
23. Naritomi Y, Terashita S, Kagayama A, and Sugiyama Y (2003) Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 31:580-588. (Pubitemid 36444167)
24. Peters SA (2008) Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet 47:261-275. (Pubitemid 351367436)
25. Poirier A, Funk C, Scherrmann JM, and Lavé T (2009) Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. Mol Pharm 6: 1716-1733.
26. Poulin P and Theil FP (2002) Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91:1358-1370. (Pubitemid 34651198)
27. Rodgers T, Leahy D, and Rowland M (2005) Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259-1276. (Pubitemid 40904190)
28. Rodgers T and Rowland M (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238-1257. (Pubitemid 43874439)
29. Shiran MR, Proctor NJ, Howgate EM, Rowland-Yeo K, Tucker GT, and Rostami-Hodjegan A (2006) Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling. Xenobiotica 36:567-580. (Pubitemid 44174445)
30. Shitara Y, Horie T, and Sugiyama Y (2006) Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425-446. (Pubitemid 43363338)
31. Tamaki S, Komura H, Kogayu M, and Yamada S (2011) Comparative assessment of empirical and physiological approaches on predicting human clearances. J Pharm Sci 100:1147-1155.
32. Tang H and Mayersohn M (2006) A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. J Pharm Sci 95: 1783-1799. (Pubitemid 44229585)
33. Tang H, Hussain A, Leal M, Mayersohn M, and Fluhler E (2007) Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos 35:1886-1893. (Pubitemid 47481583)
34. Van den Bergh A, Sinha V, Gilissen R, Straetemans R, Wuyts K, Morrison D, Bijnens L, and Mackie C (2011) Prediction of human oral plasma concentration-time profiles using preclinical data: comparative evaluation of prediction approaches in early pharmaceutical discovery. Clin Pharmacokinet 50:505-517.
35. Vuppugalla R, Marathe P, He H, Jones RD, Yates JW, Jones HM, Gibson CR, Chien JY, Ring BJ, and Adkison KK, et al. (2011) PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach. J Pharm Sci 100:4111-4126.
36. Wajima T, Yano Y, Fukumura K, and Oguma T (2004) Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J Pharm Sci 93: 1890-1900. (Pubitemid 38823714)
37. Watanabe T, Kusuhara H, Maeda K, Shitara Y, and Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652-662.
38. Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, and Sugiyama Y (2010) Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos 38:215-222.
39. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE (2004) Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208. (Pubitemid 39410902)
40. Yamazaki S, Skaptason J, Romero D, Vekich S, Jones HM, Tan W, Wilner KD, and Koudriakova T (2011) Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. Drug Metab Dispos 39:383-393.